SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 2,188.79 |
| Enterprise Value ($M) | 1,958.58 |
| Book Value ($M) | 791.32 |
| Book Value / Share | 9.94 |
| Price / Book | 2.77 |
| NCAV ($M) | 565.48 |
| NCAV / Share | 7.10 |
| Price / NCAV | 3.87 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.15 |
| Return on Assets (ROA) | -0.11 |
| Return on Equity (ROE) | -0.18 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.69 |
| Current Ratio | 5.69 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 945.53 |
| Assets | 1,171.37 |
| Liabilities | 380.05 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 7.77 | -28.51 | |
| 13G/A | BlackRock, Inc. | 9.40 | 0.00 | |
| 13G/A | Farallon Capital Partners, L.P. | 9.90 | 99.92 | |
| 13G/A | State Street Corp | 4.80 | -14.88 | |
| 13G/A | ARCH Venture Fund IX, L.P. | 6.80 | -6.26 | |
| 13G/A | Vanguard Group Inc | 8.79 | 14.21 | |
| 13G/A | Temasek Holdings (Private) Ltd | 3.80 | -15.60 | |
| 13G/A | ARK Investment Management LLC | 11.53 | 14.38 | |
| 13G/A | BlackRock Inc. | 8.20 | 27.18 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 130,717 | 604,884 | 21.61 | |
| 125,437 | 613,593 | 20.44 | |
| 258,106 | 988,712 | 26.11 | |
| 398,801 | 1,561,077 | 25.55 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BBIO – BridgeBio Pharma, Inc. | BCRX – BioCryst Pharmaceuticals, Inc. |
| BDTX – Black Diamond Therapeutics, Inc. | BIIB – Biogen Inc. |
| BLUE – bluebird bio, Inc. |
Financial data and stock pages provided by
Fintel.io